News
Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
With new treatment options for hemophilia A without inhibitors, the question of cost-effectiveness of different treatment approaches arises. The results of a model comparing replacement therapy and emicizumab in terms of cost-effectiveness were presented at a recently held ASH conference.
The World of Viruses is Constantly Evolving and Bringing Us New Surprises
The last decade has been marked by the emergence of new, as well as re-emerging human pathogens responsible...
Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
The aging population of individuals with hemophilia brings new experiences and challenges, leading…
Less Ventricular Arrhythmias and ICD Shocks After Introduction of Sacubitril/Valsartan
Is the decrease in the incidence of sudden cardiac death among patients using sacubitril/valsartan…
Diosmin – Still an Important Modality in the Treatment of Venous Insufficiency
Chronic venous insufficiency is a highly prevalent disease in the Western population. Unfortunately,...
Europe and Tooth Decay: The Situation is Improving Thanks to Fluorides and New Technologies
How to prevent tooth decay? This question has been addressed by doctors for several centuries. A…
Popular this week
- BENIGN DERMATOSIS OF PENIS
- Tuberous Sclerosis
- HCG level after embryo transfer as a prognostic indicator of pregnancy finished with delivery
- With MD Eva Drbohlavová on Innovations in the Treatment of von Willebrand Disease and Improving Patients' Quality of Life
- Fractures of the fifth metatarsal base